Trulicity is a GLP-1 receptor agonist. It increases intracellular cAMP in beta cells leading to glucose-dependent insulin release. It also decreases glucagon secretion and slows gastric emptying.
Trulicity is supplied as a solution for subcutaneous injection. The recommended initiating dose is 0.75 mg once weekly. The maximum recommended dose is 1.5 mg once weekly. Administered once weekly, any time of day, with or without food. Trulicity should be injected subcutaneously in the abdomen, thigh, or upper arm.
Victoza was approved by FDA in January 2010. It is an injectable form of GLP-1 analog. It improves diabetes via several mechanisms; insulin sensitivity, appetite suppression, reduced gastrointestinal motility, lower glucagon and higher insulin release in response to food.
A nice video summary by NEJM regarding cardiovascular benefits of semaglutide. Semaglutide was FDA approved in December 2017. It is once a week GLP-1 agonist, with cardiac, weight loss and hyperglycemic advantages.
FreeStyle Libre is the first glucometer without the use of fingersticks for measurements or calibration. It received the FDA approval in September 2017. Below is a nice video on how to apply the sensor and use the scanner.
Goldberg variations is one of the very few pieces that JS Bach published (1741) in his lifetime. It was composed for a two-manual harpsichord. It's beautifully performed here by Helmuth Walcha, a Bach scholar and legend.